• Profile
Close

Peripheral blood leukocyte N6-methyladenosine is a noninvasive biomarker for non-small-cell lung carcinoma

OncoTargets and Therapy Nov 23, 2020

Pei Y, Lou X, Li K, et al. - In this study with 119 NSCLC patients and 74 age-matched healthy controls, researchers determined if leukocyte N6-methyladenosine (m6A) can serve as a novel biomarker for non-small-cell lung cancer (NSCLC). They collected peripheral blood from participants, from which total RNA was isolated from leukocytes for m6A measurement. In NSCLC patients vs healthy controls, significantly increased leukocyte m6A was found. In ROC curve analysis, a significant ability to differentiate lung adenocarcinoma and lung squamous cell carcinoma (LUSC) cases from healthy persons was enabled by leukocyte m6A. Compared with squamous cell carcinoma antigen and cytokeratin fragment 211, a superior sensitivity (100%) as well as specificity (85.7%) for LUSC was shown by m6A. Based on these findings, leukocyte m6A was concluded to be a potential noninvasive biomarker for NSCLC screening, monitoring, as well as diagnosis.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay